Strategic partnerships TRIO collaborates with academic centers, industry partners and patient advocates to accelerate oncology drug development, presenting opportunities to co-develop trials, access new compounds, and expand investigator networks for joint BD initiatives.

translational expertise As a full-service oncology CRO with a translational research model, TRIO offers end-to-end trial execution from concept to IND readiness, making it a compelling partner for sponsors seeking efficient pathways and scientifically guided development plans.

Global network With a worldwide network of investigators and academic leaders, TRIO can help sponsors expand trials internationally, access diverse patient populations, and optimize protocol feasibility across regions.

Financial scale Annual revenue in the multi-tens of millions and a mid-size employee base indicate room for scalable collaboration, such as larger multi-center studies, consulting engagements, or expanded services in early-phase and translational research.

Brand credibility Recognition in workplace awards and a Nobel Prize related to foundational tech like quantum dots enhances credibility with stakeholders, easing discussions about innovative trial designs, imaging endpoints, and novel biomarker strategies.